Apexigen is a clinical-stage biopharmaceutical company discovering and developing the next generation of antibody therapeutics for the treatment of cancer with an emphasis on new immuno-oncology products that harness the patient’s immune system to combat and eradicate cancer. Apexigen recently presented at several investor conferences and twice at the American Association for Cancer Research (AACR) Annual Meeting.